---
$id: https://graph.org.ai/products/commodity/51202402
$type: Product
source: UNSPSC
code: "51202402"
title: "Basiliximab"
class: "51202400"
classTitle: "Immunosupressant antibodies"
family: "51200000"
familyTitle: "Immunomodulating drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Basiliximab

**UNSPSC Code**: 51202402
**Class**: [Immunosupressant antibodies](Immunosupressant antibodies.mdx)
**Family**: [Immunomodulating drugs](../Immunomodulating drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a monoclonal antibody and immunosuppressant with the molecular formula C6378H9844N1698O1997S48, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 9927MT646M, more generally known as basiliximab. European Medicines Agency schedules basiliximab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12468MIG. The term BASILIXIMAB is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 11, No. 3 1997, list 38. BASILIXIMAB is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule basiliximab under HS 30021091 and SITC 54163. As of Q4 2014, BASILIXIMAB remains US FDA's Preferred Term for this commodity. Basiliximab bears US NLM identifiers UMLS ID C0676831 and NCI Concept Code C52186. SMILES: NONE.

